Roche Financial Statements From 2010 to 2024
| RHHBF Stock | USD 306.98 4.06 1.34% |
Check Roche Holding financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Roche Holding's main balance sheet or income statement drivers, such as , as well as many indicators such as . Roche financial statements analysis is a perfect complement when working with Roche Holding Valuation or Volatility modules.
Roche |
Roche Holding AG OTC Stock Return On Equity Analysis
Roche Holding's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Roche Holding Return On Equity | 0.45 |
Most of Roche Holding's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Roche Holding AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Roche Holding AG has a Return On Equity of 0.4483. This is 101.87% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The return on equity for all United States stocks is notably lower than that of the firm.
Roche Holding AG Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Roche Holding's current stock value. Our valuation model uses many indicators to compare Roche Holding value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Roche Holding competition to find correlations between indicators driving Roche Holding's intrinsic value. More Info.Roche Holding AG is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.33 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Roche Holding AG is roughly 3.05 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Roche Holding's earnings, one of the primary drivers of an investment's value.About Roche Holding Financial Statements
Roche Holding stakeholders use historical fundamental indicators, such as Roche Holding's revenue or net income, to determine how well the company is positioned to perform in the future. Although Roche Holding investors may analyze each financial statement separately, they are all interrelated. For example, changes in Roche Holding's assets and liabilities are reflected in the revenues and expenses on Roche Holding's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Roche Holding AG. Please read more on our technical analysis and fundamental analysis pages.
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company was founded in 1896 and is headquartered in Basel, Switzerland. ROCHE HOLDINGS operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 100920 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Roche OTC Stock
Roche Holding financial ratios help investors to determine whether Roche OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Roche with respect to the benefits of owning Roche Holding security.